Chronic Myeloproliferative Disorders Terminated Phase 2 Trials for Fludarabine (DB01073)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00281879Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerTreatment
NCT00069992Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CMLTreatment
NCT00066417Peripheral Stem Cell Transplant in Treating Patients With High-Risk LeukemiaTreatment